HIKMA PHARMACEUTICALS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,980 GBX | -0.73% |
|
+1.12% | +10.56% |
| May. 03 | Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy | MT |
| May. 03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
ETFs positioned on Hikma Pharmaceuticals PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -2.25% | - | |
| 0.00% | 0 M€ | -2.58% | - |
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
24.95
USD
Average target price
28.68
USD
Spread / Average Target
+14.92%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.56% | 5.54B | |
| +30.38% | 684B | |
| +29.16% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.31% | 240B | |
| +8.95% | 208B | |
| -7.73% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- HIK Stock
- Funds and ETFs Hikma Pharmaceuticals PLC